Free Trial
NASDAQ:OPTN

OptiNose Q4 2024 Earnings Report

OptiNose logo
$9.40 +0.01 (+0.11%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$9.40 0.00 (0.00%)
As of 05/2/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OptiNose EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.70
Beat/Miss
Beat by +$0.67
One Year Ago EPS
N/A

OptiNose Revenue Results

Actual Revenue
$21.47 million
Expected Revenue
$21.02 million
Beat/Miss
Beat by +$445.00 thousand
YoY Revenue Growth
N/A

OptiNose Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

OptiNose's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 10:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

OptiNose Earnings Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Optinose reports Q4 EPS (3c) vs ($1.33) last year
See More OptiNose Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiNose? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiNose and other key companies, straight to your email.

About OptiNose

OptiNose (NASDAQ:OPTN), a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

View OptiNose Profile

More Earnings Resources from MarketBeat